is the Founder of ABT and will be responsible for the overall success of ABT and for making top-level managerial decisions. A world-renowned scientist (over 350 scientific publications and 1 patent and 5 pending patents) and an experienced administrator with 25 years of executive management, Alexzander will be responsible for leading the development and execution of this initiative. As the CEO, Alexzander reports directly to, and is accountable to, the Board of Directors for the performance of ABT

is a Founding member of ABT and will be responsible for translating and implementing the overall product vision and go-to-market strategy of NBT’s full product and service portfolio. Hossein has been instrumental in building innovative solutions that not only solve substantial client based existing challenges, but address opportunities driven by the monumental shifts occurring in pharmaceutical drug manufacturing, and the development and implementation of an agile product prioritization and development process that appropriately balances innovation, speed, quality and scale.

is currently the Director for Molecular and Cellular Radiation Oncology at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. Dr Calderwood is world renown for his research on the design of molecular chaperone-based vaccines and on the development of compounds targeting breast cancer. Prof Calderwood is also the Founder & CEO of Chaperonix, a biopharmaceutical company focused on molecular chaperone research.

Is the Co-Leader, Gastrointestinal Cancer Program, Mayo Clinic Cancer Center, Endowed Chair, Florida Department of Health, Radiation Oncology, Mayo Clinic, and Chair, Scientific Program and Education Committees, ASTRO Academy. Dr Krishnan specializes in the radiotherapy treatment of gastrointestinal cancers. Research in Dr. Krishnan’s Nanotechnology and Radiation Biology Laboratory includes strategies to sensitize tumors to radiation therapy using nanoparticles, chemotherapy, botanicals, immunotherapy and novel radiation techniques including particle therapy, mini beams and boron neutron capture therapy. He evaluates approaches to protect normal tissues from radiation injury using novel agents. Dr. Krishnan also studies patterns of gene expression and imaging characteristics in human tumors that predict response to radiotherapy and chemotherapy. His research has been funded by the National Institutes of Health for over a decade. Dr. Krishnan’s focus areas include; Nanotechnology, Drug-radiation interactions, High-linear energy transfer (LET) treatments, Novel therapeutic modalities and Predictors of radiotherapy outcome.

is currently Professor at the Technical University Munich, and Director of the Celleurope Project, and leads the Department of Experimental Radiooncology and Radiobiology and is also the leader of the Clinical Cooperation Group (CCG) at the Technical University, Munich, Germany. Prof. Multhoff is also a Commissioner of the German Academic Exchange Service (DAAD) in the EU. Dr Multhoff is also the Founder and CEO of Multimmune GmbH, a biopharmaceutical company focused on the development of innovative therapeutic approaches for the treatment of cancers that express heat shock proteins.